Aratana Therapeutics to Present at the 2014 Animal & Dental Health Summit

Dec 05, 2014, 12:13 ET from Aratana Therapeutics, Inc.

KANSAS CITY, Kan., Dec. 5, 2014 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will present at the 2014 Animal & Dental Health Summit, to be held December 11-12, 2014, at the Bank of America Merrill Lynch Conference Center in Boston, MA.

Steven St. Peter, M.D., President and Chief Executive Officer, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference. 

Event:


2014 Animal & Dental Health Summit

Date: 


Thursday, December 11, 2014 

Time: 


8:55 am (Eastern Time) 

Location:


Bank of America Merrill Lynch Conference Center

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The Company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions.  Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets.  For more information, please visit www.aratana.com.  

Contacts:
For investor inquires:
Aratana Therapeutics, Inc.
Craig Tooman
ctooman@aratana.com; (913) 353-1023

For media inquiries:
Tiberend Strategic Advisors, Inc.
Andrew Mielach
amielach@tiberend.com; (212) 375-2694

SOURCE Aratana Therapeutics, Inc.



RELATED LINKS

http://www.aratana.com